Summary

The oligonucleotide synthesis market is projected to reach USD 32.72 billion by 2031, up from USD 14.64 billion in 2026, at a CAGR of 17.4% over the forecast period. Market growth is driven by several factors, including increasing demand for synthesized oligonucleotides such as primers and probes for research and diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
By offering, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.

The market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides and oligonucleotide synthesis products (consumables and equipment). In 2025, the oligonucleotide-based drugs segment accounted for the largest share of the market. This large share reflects growing acceptance of these treatments and their proven success, especially for rare and hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.

In 2025, North America accounted for the largest share of the overall oligonucleotide synthesis market.
The US is the largest market for oligonucleotide synthesis, driving North America's commanding share of global market revenue. This dominance is propelled by a dense ecosystem of major biopharmaceutical companies, world-class academic research institutes, and extensive venture capital investment in genomic innovation. Furthermore, a massive clinical drug pipeline featuring over 150 oligo-based therapeutics, coupled with clear, supportive regulatory frameworks from the US FDA, drives demand for complex, large-scale, high-purity GMP production at a level unmatched by any other nation.
The primary interviews conducted for this report can be categorized as follows:

・ By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
・ By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
・ By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%
Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering oligonucleotide synthesis products and synthesized oligonucleotides.
Biogen (US) Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies offering oligonucleotide-based drugs, profiled in the report.

Research Coverage:
This research report categorizes oligonucleotide synthesis market by offering (oligonucleotide-based drugs, synthesized oligonucleotides, oligonucleotide synthesis products); oligonucleotide-based drugs (by type: antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, other oligonucleotide-based drugs; by therapeutic area: rare diseases, cardiometabolic diseases, neurology, other therapeutic areas; by end user: hospitals, specialty clinics, home care settings, other end users); synthesized oligonucleotides (by oligo type: primers, probes, DNA oligos, RNA oligos, other oligos; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories); oligonucleotide synthesis products (by type: consumables, oligo synthesis equipment; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide synthesis market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, product offerings, key strategies, new product launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report also covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.

Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
・ Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing R&D investments by key players in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
・ Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market
・ Market Development: Comprehensive information about lucrative markets – the report analyzes the oligonucleotide synthesis market across varied regions
・ Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market
・ Pipeline Analysis: Comprehensive information about oligonucleotide-based drugs under clinical trials
・ Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others, offering oligonucleotide synthesis products and synthesized oligonucleotides. Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), and Sarepta Therapeutics, Inc. (US) are key players in the oligonucleotide-based drugs segment of this market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 63
1.1 STUDY OBJECTIVES 63
1.2 MARKET DEFINITION 64
1.3 STUDY SCOPE 64
1.3.1 MARKET SEGMENTATION & REGIONS COVERED 65
1.3.2 REGIONS COVERED 66
1.3.3 INCLUSIONS & EXCLUSIONS 66
1.3.4 YEARS CONSIDERED 68
1.3.5 CURRENCY CONSIDERED 68
1.4 STAKEHOLDERS 68
1.5 SUMMARY OF CHANGES 69
2 EXECUTIVE SUMMARY 70
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 70
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 72
2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 74
2.4 HIGH-GROWTH SEGMENTS 75
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 76
3 PREMIUM INSIGHTS 78
3.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 78
3.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY OFFERING AND COUNTRY, 2025 79
3.3 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 80
3.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%) 81
4 MARKET OVERVIEW 82
4.1 INTRODUCTION 82
4.2 MARKET DYNAMICS 82
4.2.1 DRIVERS 83
4.2.1.1 Rising commercialization and regulatory approvals of oligonucleotide therapeutics 83
4.2.1.2 Expanding RNA therapeutics pipeline and adoption of chemically modified oligos 84
4.2.1.3 Growing use of PCR, qPCR, NGS, CRISPR, synthetic biology, and molecular diagnostics 85
4.2.1.4 Increasing outsourcing of oligonucleotide synthesis and GMP manufacturing to CROs/CDMOs 85
4.2.2 RESTRAINTS 86
4.2.2.1 Complexity of large-scale oligonucleotide manufacturing and analytical control 86
4.2.3 OPPORTUNITIES 86
4.2.3.1 Increasing government and industry investments in life sciences, RNA therapeutics, and manufacturing infrastructure 86
4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases 88
4.2.3.3 Growth of companion diagnostics and precision medicine 88
4.2.4 CHALLENGES 89
4.2.4.1 Lack of standard regulations 89
4.2.4.2 Delivery of oligonucleotide drugs to specific targets 89
4.2.4.3 Sustainability & waste management in phosphoramidite-based synthesis 90
4.3 UNMET NEEDS & WHITE SPACES 90
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 90
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 91
4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET 91
4.5.2 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET 92
5 INDUSTRY TRENDS 93
5.1 PORTER’S FIVE FORCES ANALYSIS 93
5.1.1 OLIGONUCLEOTIDE-BASED DRUGS 93
5.1.1.1 Threat of new entrants 94
5.1.1.2 Threat of substitutes 94
5.1.1.3 Bargaining power of buyers 94
5.1.1.4 Bargaining power of suppliers 94
5.1.1.5 Intensity of competitive rivalry 94
5.1.2 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE
SYNTHESIS PRODUCTS 95
5.1.2.1 Threat of new entrants 96
5.1.2.2 Threat of substitutes 96
5.1.2.3 Bargaining power of buyers 96
5.1.2.4 Bargaining power of suppliers 96
5.1.2.5 Intensity of competitive rivalry 96
5.2 MACROECONOMIC OUTLOOK 97
5.2.1 INTRODUCTION 97
5.2.2 GDP TRENDS & FORECAST 97
5.2.3 TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET 98
5.3 VALUE CHAIN ANALYSIS 98
5.4 ECOSYSTEM ANALYSIS 100
5.5 PRICING ANALYSIS 101
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER,
2022–2025 102
5.5.2 AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025 104
5.6 KEY CONFERENCES & EVENTS, 2026–2027 105
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 105
5.8 INVESTMENT & FUNDING ACTIVITY 107
5.9 IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET 108
5.9.1 INTRODUCTION 108
5.9.2 KEY TARIFF RATES 108
5.9.3 PRICE IMPACT ANALYSIS 109
5.9.4 IMPACT ON COUNTRY/REGION 110
5.9.4.1 North America 110
5.9.4.2 Europe 110
5.9.4.3 Asia Pacific 111
5.9.5 IMPACT ON END-USE INDUSTRIES 111
5.9.5.1 Hospitals 111
5.9.5.2 Specialty clinics 112
5.9.5.3 Home care settings & other end users 112
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 113
6.1 TECHNOLOGY ANALYSIS 113
6.1.1 KEY TECHNOLOGIES 113
6.1.1.1 Solid-phase phosphoramidite synthesis and scale-up 113
6.1.1.2 Liquid-phase synthesis 113
6.1.1.3 Chemical modification & backbone engineering 114
6.1.1.4 Conjugation & targeted delivery chemistry 114
6.1.1.5 Enzymatic & novel synthesis technologies 114
6.1.1.6 High-throughput automated oligonucleotide synthesis 114
6.1.1.7 Purification & analytical characterization 115
6.1.2 ADJACENT TECHNOLOGIES 115
6.1.2.1 Molecular biology & genomic technologies 115
6.1.2.2 Synthetic biology & gene synthesis 115
6.1.3 COMPLEMENTARY TECHNOLOGIES 116
6.1.3.1 Advanced oligonucleotide delivery technologies 116
6.1.3.2 AI-assisted oligonucleotide design 116
6.2 TECHNOLOGY/PRODUCT ROADMAP 116
6.3 FUTURE APPLICATIONS 117
6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET 117
6.4.1 TOP USE CASES & MARKET POTENTIAL 118
6.4.2 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 119
6.4.3 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET 119
6.5 PATENT ANALYSIS & INNOVATIONS 120
6.5.1 OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015–2025 121
6.5.2 KEY INNOVATIONS 122
7 SUSTAINABILITY & REGULATORY LANDSCAPE 123
7.1 REGIONAL REGULATIONS & COMPLIANCE 123
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123
7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT 126
7.1.2.1 North America 126
7.1.2.2 Europe 126
7.1.2.3 Asia Pacific 126
7.1.2.4 Rest of the World 126
7.1.3 INDUSTRY STANDARDS 127
7.2 REIMBURSEMENT SCENARIO 127
7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 130
7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 130
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 132
8.1 DECISION-MAKING PROCESS 132
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 132
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 132
8.2.2 KEY BUYING CRITERIA, BY END USER 133
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 134
8.4 UNMET NEEDS FROM END USERS 135
8.5 MARKET PROFITABILITY 135
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING 136
9.1 INTRODUCTION 137
9.2 OLIGONUCLEOTIDE-BASED DRUGS 137
9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH 137
9.3 SYNTHESIZED OLIGONUCLEOTIDES 142
9.3.1 GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS 142
9.4 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 145
9.4.1 INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH 145
10 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 149
10.1 INTRODUCTION 150
10.2 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS 150
10.2.1 ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND
NEUROLOGICAL DISEASES 150
10.3 SIRNA OLIGONUCLEOTIDE-BASED DRUGS 155
10.3.1 EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH 155
10.4 OTHER OLIGONUCLEOTIDE-BASED DRUGS 159
11 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA 164
11.1 INTRODUCTION 165
11.2 RARE DISEASES 165
11.2.1 GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS 165
11.3 NEUROLOGICAL DISORDERS 169
11.3.1 COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT 169
11.4 CARDIOMETABOLIC DISEASES 173
11.4.1 EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA 173
11.5 OTHER THERAPEUTIC AREAS 177
12 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER 180
12.1 INTRODUCTION 181
12.2 SPECIALTY CLINICS 181
12.2.1 GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT 181
12.3 HOSPITALS 185
12.3.1 COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND 185
12.4 HOME CARE SETTINGS 189
12.4.1 SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT 189
12.5 OTHER END USERS 193
13 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE 198
13.1 INTRODUCTION 199
13.2 PRIMERS 199
13.2.1 WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH 199
13.3 PROBES 203
13.3.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES 203
13.4 DNA OLIGONUCLEOTIDES 206
13.4.1 BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS 206
13.5 RNA OLIGONUCLEOTIDES 210
13.5.1 RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS 210
13.6 OTHER OLIGONUCLEOTIDES 213
14 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 217
14.1 INTRODUCTION 218
14.2 CUSTOM OLIGONUCLEOTIDES 218
14.2.1 RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT 218
14.3 PREDESIGNED OLIGONUCLEOTIDES 222
14.3.1 PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS 222
15 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION 226
15.1 INTRODUCTION 227
15.2 RESEARCH APPLICATIONS 227
15.2.1 PCR 231
15.2.1.1 Widespread adoption of PCR across life science research to drive market growth 231
15.2.2 NGS 235
15.2.2.1 Sequencing to continue to expand with increasing adoption of next-generation sequencing technologies 235
15.2.3 OTHER RESEARCH APPLICATIONS 238
15.3 THERAEPUTIC DEVELOPMENT 241
15.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS 241
15.4 DIAGNOSTIC APPLICATIONS 244
15.4.1 INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS 244
16 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER 248
16.1 INTRODUCTION 249
16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 249
16.2.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT 249
16.3 CROS & CDMOS 253
16.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS 253
16.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES 256
16.4.1 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND 256
16.5 ACADEMIC & RESEARCH INSTITUTES 260
16.5.1 EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES 260
17 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE 264
17.1 INTRODUCTION 265
17.2 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES 265
17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS 270
17.2.1.1 Phosphoramidite building blocks 274
17.2.1.1.1 DNA phosphoramidites 278
17.2.1.1.1.1 Steady, high-volume primer, probe, and gene-synthesis demand to anchor DNA phosphoramidites as largest phosphoramidite revenue category 278
17.2.1.1.2 RNA phosphoramidites 282
17.2.1.1.2.1 Expansion of siRNA and CRISPR guide RNA therapeutic pipeline to make RNA phosphoramidites fastest-growing phosphoramidite category 282
17.2.1.1.3 Modified phosphoramidites 285
17.2.1.1.3.1 Modified phosphoramidites to continue to gain importance as oligonucleotide complexity increases 285
17.2.1.2 Activators/Coupling reagents 289
17.2.1.2.1 Migration from standard tetrazole to ETT- and BTT-based activators to raise coupling efficiency in GMP-scale RNA and modified-oligo synthesis 289
17.2.1.3 Deprotection reagents 292
17.2.1.3.1 Rising synthesis throughput and demand for milder, modification-compatible deprotection chemistries to sustain detritylation reagent consumption 292
17.2.1.4 Capping reagents 296
17.2.1.4.1 Tightening n-1 impurity specifications for therapeutic oligonucleotides to lift demand for validated, high-purity capping reagent lots 296
17.2.1.5 Other reagents 299
17.2.2 SOLID SUPPORTS 302
17.2.2.1 Shift toward high-loading co-polymer CPG and single-use synthesis cassettes to support long-chain, GMP-scale oligonucleotide production 302
17.2.3 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES 306
17.2.3.1 Tightening GMP purity specifications for therapeutic oligonucleotides to drive demand for purification and QC consumables 306
17.3 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT 309
17.3.1 ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION 309
18 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION 313
18.1 INTRODUCTION 314
18.2 RESEARCH APPLICATIONS 314
18.2.1 HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH 314
18.3 THERAPEUTIC DEVELOPMENT 318
18.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET 318
18.4 DIAGNOSTIC APPLICATIONS 321
18.4.1 DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE 321
19 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER 325
19.1 INTRODUCTION 326
19.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 326
19.2.1 INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH 326
19.3 CROS & CDMOS 330
19.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH 330
19.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES 334
19.4.1 EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND 334
19.5 ACADEMIC & RESEARCH INSTITUTES 337
19.5.1 ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH 337
20 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 341
20.1 INTRODUCTION 342
20.2 NORTH AMERICA 342
20.2.1 US 351
20.2.1.1 Mature ecosystem across oligo-based therapeutics, synthesized oligonucleotides, and oligonucleotide synthesis products to drive market growth 351
20.2.2 CANADA 359
20.2.2.1 Strong academic research ecosystem to support market growth 359
20.3 EUROPE 367
20.3.1 GERMANY 375
20.3.1.1 Established capabilities for development and manufacturing of
oligo-based therapeutics to drive market growth 375
20.3.2 UK 383
20.3.2.1 Established national programs to encourage utilization of oligonucleotide synthesis products 383
20.3.3 FRANCE 391
20.3.3.1 Increase in RNA-related research by biotechnology companies and academic institutions to drive market growth 391
20.3.4 ITALY 399
20.3.4.1 High demand for molecular diagnostics to favor adoption of oligonucleotide synthesis products 399
20.3.5 SPAIN 406
20.3.5.1 Government organizations investing in oligonucleotide-related research activities to drive market growth 406
20.3.6 REST OF EUROPE 413
20.4 ASIA PACIFIC 421
20.4.1 JAPAN 430
20.4.1.1 Expanding collaboration between pharma companies and academic institutions for development of oligonucleotide therapeutics to drive market growth 430
20.4.2 CHINA 438
20.4.2.1 Robust network of domestic companies offering oligonucleotide products to support market growth 438
20.4.3 INDIA 446
20.4.3.1 Expanding presence of domestic service providers to offer high-quality DNA and RNA oligonucleotides for research and diagnostics 446
20.4.4 SOUTH KOREA 453
20.4.4.1 High demand for custom oligonucleotide synthesis services to support market growth 453
20.4.5 AUSTRALIA 461
20.4.5.1 Well-established biomedical research sector to favor utilization of oligonucleotide synthesis products 461
20.4.6 REST OF ASIA PACIFIC 469
20.5 LATIN AMERICA 477
20.5.1 BRAZIL 485
20.5.1.1 Government initiatives aimed at strengthening genomic surveillance to offer market expansion opportunities 485
20.5.2 MEXICO 493
20.5.2.1 Growing network of pharmaceutical manufacturers and diagnostic laboratories to offer market expansion opportunities 493
20.5.3 ARGENTINA 501
20.5.3.1 Increasing investment by academic institutions in oligonucleotide-based research to offer market expansion opportunities 501
20.5.4 REST OF LATIN AMERICA 506
20.6 MIDDLE EAST 511
20.6.1 GCC COUNTRIES 519
20.6.1.1 Saudi Arabia 527
20.6.1.1.1 National genomics initiatives to encourage adoption of oligonucleotide synthesis products 527
20.6.1.2 UAE 535
20.6.1.2.1 Government-driven initiatives and substantial investments to improve UAE's capabilities in life science industry 535
20.6.1.3 Rest of GCC Countries 543
20.6.2 REST OF MIDDLE EAST 551
20.7 AFRICA 559
20.7.1 GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH 559
21 COMPETITIVE LANDSCAPE 567
21.1 INTRODUCTION 567
21.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 567
21.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023–2026 567
21.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023–2026 569
21.3 REVENUE ANALYSIS, 2021–2025 572
21.3.1 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET,
2021–2025 572
21.3.2 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021–2025 572
21.4 MARKET SHARE ANALYSIS, 2025 573
21.4.1 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025 573
21.4.2 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025 575
21.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025 578
21.5.1 STARS 578
21.5.2 EMERGING LEADERS 578
21.5.3 PERVASIVE PLAYERS 578
21.5.4 PARTICIPANTS 578
21.5.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025 580
21.5.5.1 Company footprint 580
21.5.5.2 Region footprint 580
21.5.5.3 Drug type footprint 581
21.5.5.4 Therapeutic area footprint 582
21.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025 582
21.6.1 STARS 583
21.6.2 EMERGING LEADERS 583
21.6.3 PERVASIVE PLAYERS 583
21.6.4 PARTICIPANTS 583
21.6.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025 585
21.6.5.1 Company footprint 585
21.6.5.2 Region footprint 586
21.6.5.3 Product type footprint 587
21.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 588
21.7.1 PROGRESSIVE COMPANIES 588
21.7.2 RESPONSIVE COMPANIES 588
21.7.3 DYNAMIC COMPANIES 588
21.7.4 STARTING BLOCKS 588
21.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 590
21.7.5.1 Detailed list of key startups/SMEs 590
21.7.5.2 Competitive benchmarking of key startups/SMEs 591
21.8 BRAND/PRODUCT COMPARATIVE ANALYSIS 592
21.9 COMPANY VALUATION & FINANCIAL METRICS 594
21.9.1 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS 594
21.9.2 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS 595
21.10 COMPETITIVE SCENARIO 596
21.10.1 PRODUCT APPROVALS 596
21.10.2 DEALS 597
21.10.3 EXPANSIONS 598
22 COMPANY PROFILES 600
22.1 OLIGONUCLEOTIDE-BASED DRUG COMPANIES 600
22.1.1 ALNYLAM PHARMACEUTICALS, INC. 600
22.1.1.1 Business overview 600
22.1.1.2 Products offered 601
22.1.1.3 Recent developments 602
22.1.1.3.1 Product approvals 602
22.1.1.3.2 Deals 602
22.1.1.3.3 Expansions 603
22.1.1.4 MnM view 603
22.1.1.4.1 Key strengths 603
22.1.1.4.2 Strategic choices 603
22.1.1.4.3 Weaknesses & competitive threats 603
22.1.2 BIOGEN INC. 604
22.1.2.1 Business overview 604
22.1.2.2 Products offered 605
22.1.2.3 Recent developments 606
22.1.2.3.1 Product approvals 606
22.1.2.3.2 Deals 606
22.1.2.3.3 Expansions 607
22.1.2.4 MnM view 607
22.1.2.4.1 Key strengths 607
22.1.2.4.2 Strategic choices 607
22.1.2.4.3 Weaknesses & competitive threats 607
22.1.3 NOVARTIS AG 608
22.1.3.1 Business overview 608
22.1.3.2 Products offered 609
22.1.3.3 Recent developments 610
22.1.3.3.1 Product approvals 610
22.1.3.3.2 Deals 610
22.1.3.4 MnM view 611
22.1.3.4.1 Key strengths 611
22.1.3.4.2 Strategic choices 611
22.1.3.4.3 Weaknesses & competitive threats 611
22.1.4 SAREPTA THERAPEUTICS, INC. 612
22.1.4.1 Business overview 612
22.1.4.2 Products offered 613
22.1.4.3 Recent developments 614
22.1.4.3.1 Product approvals 614
22.1.4.3.2 Deals 614
22.1.4.3.3 Expansions 614
22.1.4.4 MnM view 615
22.1.4.4.1 Key strengths 615
22.1.4.4.2 Strategic choices 615
22.1.4.4.3 Weaknesses & competitive threats 615
22.1.5 ASTELLAS PHARMA INC. 616
22.1.5.1 Business overview 616
22.1.5.2 Products offered 617
22.1.5.3 Recent developments 618
22.1.5.3.1 Product approvals 618
22.1.5.3.2 Deals 618
22.1.5.4 MnM view 619
22.1.5.4.1 Key strengths 619
22.1.5.4.2 Strategic choices 619
22.1.5.4.3 Weaknesses & competitive threats 619
22.1.6 ASTRAZENECA 620
22.1.6.1 Business overview 620
22.1.6.2 Products offered 621
22.1.6.3 Recent developments 622
22.1.6.3.1 Product approvals 622
22.1.6.3.2 Deals 622
22.1.7 JAZZ PHARMACEUTICALS PLC 623
22.1.7.1 Business overview 623
22.1.7.2 Products offered 624
22.1.8 GERON CORPORATION 625
22.1.8.1 Business overview 625
22.1.8.2 Products offered 626
22.1.8.3 Recent developments 626
22.1.8.3.1 Product approvals 626
22.1.8.3.2 Deals 626
22.1.9 IONIS PHARMACEUTICALS, INC. 627
22.1.9.1 Business overview 627
22.1.9.2 Products offered 628
22.1.9.3 Recent developments 629
22.1.9.3.1 Product approvals 629
22.1.9.3.2 Deals 630
22.1.9.3.3 Expansions 630
22.1.10 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.) 631
22.1.10.1 Business overview 631
22.1.10.2 Products offered 632
22.1.10.3 Recent developments 633
22.1.10.3.1 Deals 633
22.1.11 NOVO NORDISK A/S 634
22.1.11.1 Business overview 634
22.1.11.2 Products offered 635
22.1.11.3 Recent developments 636
22.1.11.3.1 Product approvals 636
22.1.12 ARROWHEAD PHARMACEUTICALS, INC. 637
22.1.12.1 Business overview 637
22.1.12.2 Products offered 638
22.1.12.3 Recent developments 638
22.1.12.3.1 Product launches & approvals 638
22.1.12.3.2 Deals 639
22.1.13 SANOFI 640
22.1.13.1 Business overview 640
22.1.13.2 Products offered 641
22.1.13.3 Recent developments 642
22.1.13.3.1 Product approvals 642
22.2 OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES 643
22.2.1 THERMO FISHER SCIENTIFIC INC. 643
22.2.1.1 Business overview 643
22.2.1.2 Products offered 644
22.2.1.3 Recent developments 647
22.2.1.3.1 Expansions 647
22.2.1.4 MnM view 647
22.2.1.4.1 Key strengths 647
22.2.1.4.2 Strategic choices 647
22.2.1.4.3 Weaknesses & competitive threats 647
22.2.2 MERCK KGAA 648
22.2.2.1 Business overview 648
22.2.2.2 Products offered 649
22.2.2.3 Recent developments 652
22.2.2.3.1 Expansions 652
22.2.2.4 MnM view 653
22.2.2.4.1 Key strengths 653
22.2.2.4.2 Strategic choices 653
22.2.2.4.3 Weaknesses & competitive threats 653
22.2.3 DANAHER CORPORATION 654
22.2.3.1 Business overview 654
22.2.3.2 Products offered 655
22.2.3.3 Recent developments 659
22.2.3.3.1 Service launches 659
22.2.3.3.2 Deals 659
22.2.3.3.3 Expansions 659
22.2.3.4 MnM view 660
22.2.3.4.1 Key strengths 660
22.2.3.4.2 Strategic choices 660
22.2.3.4.3 Weaknesses & competitive threats 660
22.2.4 EUROFINS SCIENTIFIC 661
22.2.4.1 Business overview 661
22.2.4.2 Products offered 662
22.2.4.3 Recent developments 663
22.2.4.3.1 Deals 663
22.2.4.3.2 Expansions 664
22.2.4.4 MnM view 664
22.2.4.4.1 Key strengths 664
22.2.4.4.2 Strategic choices 664
22.2.4.4.3 Weaknesses & competitive threats 664
22.2.5 AGILENT TECHNOLOGIES, INC. 665
22.2.5.1 Business overview 665
22.2.5.2 Products offered 666
22.2.5.3 Recent developments 668
22.2.5.3.1 Deals 668
22.2.5.3.2 Expansions 668
22.2.6 LGC LIMITED 669
22.2.6.1 Business overview 669
22.2.6.2 Products offered 670
22.2.6.3 Recent developments 672
22.2.6.3.1 Deals 672
22.2.6.4 MnM view 672
22.2.6.4.1 Key strengths 672
22.2.6.4.2 Strategic choices 672
22.2.6.4.3 Weaknesses & competitive threats 673
22.2.7 TWIST BIOSCIENCE 674
22.2.7.1 Business overview 674
22.2.7.2 Products offered 675
22.2.7.3 Recent developments 676
22.2.7.3.1 Product/Service launches 676
22.2.7.3.2 Deals 676
22.2.8 GENSCRIPT 677
22.2.8.1 Business overview 677
22.2.8.2 Products offered 678
22.2.8.3 Recent developments 680
22.2.8.3.1 Product/Service launches 680
22.2.8.3.2 Deals 680
22.2.8.3.3 Expansions 680
22.2.9 MARAVAI LIFESCIENCES 681
22.2.9.1 Business overview 681
22.2.9.2 Products offered 682
22.2.9.3 Recent developments 685
22.2.9.3.1 Product/Service launches 685
22.2.9.3.2 Deals 686
22.2.9.3.3 Expansions 686
22.2.9.4 MnM view 687
22.2.9.4.1 Key strengths 687
22.2.9.4.2 Strategic choices 687
22.2.9.4.3 Weaknesses & competitive threats 687
22.2.10 KANEKA CORPORATION 688
22.2.10.1 Business overview 688
22.2.10.2 Products offered 689
22.2.10.3 Recent developments 691
22.2.10.3.1 Expansions 691
22.2.11 AZENTA US INC. 692
22.2.11.1 Business overview 692
22.2.11.2 Products offered 693
22.2.11.3 Recent developments 694
22.2.11.3.1 Product/Service launches 694
22.2.11.3.2 Deals 694
22.2.12 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S) 695
22.2.12.1 Business overview 695
22.2.12.2 Products offered 695
22.2.13 BIOLEGIO B.V. 696
22.2.13.1 Business overview 696
22.2.13.2 Products offered 697
22.2.14 BIOLYTIC LAB PERFORMANCE, INC. 698
22.2.14.1 Business overview 698
22.2.14.2 Products offered 698
22.2.14.3 Recent developments 699
22.2.14.3.1 Product/Service launches 699
22.2.15 REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.) 700
22.2.15.1 Business overview 700
22.2.15.2 Products offered 702
22.2.15.3 Recent developments 703
22.2.15.3.1 Product/Service launches 703
22.2.16 BIO-SYNTHESIS, INC. 704
22.2.16.1 Business overview 704
22.2.16.2 Products offered 704
22.2.17 CREATIVE BIOGENE 707
22.2.17.1 Business overview 707
22.2.17.2 Products offered 707
22.2.18 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE) 710
22.2.18.1 Business overview 710
22.2.18.2 Products offered 711
22.2.19 BIOCOMMA LIMITED 712
22.2.19.1 Business overview 712
22.2.19.2 Products offered 712
23 RESEARCH METHODOLOGY 716
23.1 RESEARCH DATA 716
23.1.1 SECONDARY DATA 717
23.1.1.1 Key secondary sources 717
23.1.1.2 Key data from secondary research 717
23.1.2 PRIMARY DATA 718
23.1.2.1 Key primary participants 718
23.1.2.2 Breakdown of primary interviews 719
23.1.2.3 Key data from primary sources 719
23.2 MARKET SIZE ESTIMATION 720
23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025 720
23.2.1.1 Approach 1: Company revenue analysis-based estimation
(bottom-up) 720
23.2.1.2 Approach 2: Secondary research 722
23.2.1.3 Approach 3: Primary research 722
23.2.1.4 Key industry insights 723
23.2.1.5 Approach 3: MnM repository analysis 723
23.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025 724
23.3 MARKET GROWTH RATE PROJECTIONS 726
23.4 DATA TRIANGULATION 729
23.5 RESEARCH ASSUMPTIONS 730
23.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 731
24 APPENDIX 732
24.1 DISCUSSION GUIDE 732
24.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 739
24.3 CUSTOMIZATION OPTIONS 741
24.4 RELATED REPORTS 741
24.5 AUTHOR DETAILS 742

ページTOPに戻る

List of Tables/Graphs

TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS 66.
TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 83.
TABLE 3 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 94.
TABLE 4 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS 96.
TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM 101.
TABLE 6 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023–2025 102.
TABLE 7 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYER, 2023–2025 103.
TABLE 8 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS, BY REGION, 2025 104.
TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 105.
TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES 108.
TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET 119.
TABLE 12 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET 120.
TABLE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025 121.
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 123.
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124.
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 124.
TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125.
TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 125.
TABLE 19 REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS 128.
TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%) 133.
TABLE 21 KEY BUYING CRITERIA, BY END USER 133.
TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 137.
TABLE 23 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 138.
TABLE 24 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138.
TABLE 25 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 26 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139.
TABLE 27 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140.
TABLE 28 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 140.
TABLE 29 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141.
TABLE 30 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT, 2024–2031 (VIALS/PREFILLED SYRINGES) 141.
TABLE 31 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 142.
TABLE 32 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 33 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 143.
TABLE 34 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 35 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144.
TABLE 36 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 37 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145.
TABLE 38 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146.
TABLE 40 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 41 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 147.
TABLE 42 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 43 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION) 148.
TABLE 44 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148.
TABLE 45 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024–2031 (USD MILLION) 150.
TABLE 46 APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS 151.
TABLE 47 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 152.
TABLE 48 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152.
TABLE 49 EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 50 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153.
TABLE 51 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154.
TABLE 52 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 154.
TABLE 53 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155.
TABLE 54 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 155.
TABLE 55 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 156.
TABLE 56 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156.
TABLE 57 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 58 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157.
TABLE 59 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158.
TABLE 60 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 158.
TABLE 61 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159.
TABLE 62 OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS 159.
TABLE 63 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 160.
TABLE 64 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160.
TABLE 65 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 66 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161.
TABLE 67 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 162.
TABLE 68 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024–2031 (USD MILLION) 162.
TABLE 69 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163.
TABLE 70 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 165.
TABLE 71 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION) 166.
TABLE 72 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 166.
TABLE 73 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 74 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 167.
TABLE 75 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 168.
TABLE 76 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024–2031 (USD MILLION) 168.
TABLE 77 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 169.
TABLE 78 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 170.
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 170.
TABLE 80 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 171.
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 172.
TABLE 83 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024–2031 (USD MILLION) 172.
TABLE 84 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024–2031 (USD MILLION) 173.
TABLE 85 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 174.
TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 174.
TABLE 87 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 175.
TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 176.
TABLE 90 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024–2031 (USD MILLION) 176.
TABLE 91 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 177.
TABLE 92 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024–2031 (USD MILLION) 178.
TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 178.
TABLE 94 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 95 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024–2031 (USD MILLION) 179.
TABLE 96 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024–2031 (USD MILLION) 181.
TABLE 97 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 98 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 182.
TABLE 99 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 100 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 183.
TABLE 101 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 184.
TABLE 102 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION) 184.
TABLE 103 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 185.
TABLE 104 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 186.
TABLE 105 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 186.
TABLE 106 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 107 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 187.
TABLE 108 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 188.
TABLE 109 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024–2031 (USD MILLION) 188.
TABLE 110 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 189.
TABLE 111 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION) 190.
TABLE 112 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 190.
TABLE 113 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 114 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 191.
TABLE 115 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 192.
TABLE 116 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024–2031 (USD MILLION) 192.
TABLE 117 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 193.
TABLE 118 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 194.
TABLE 119 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 194.
TABLE 120 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 121 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 195.
TABLE 122 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 196.
TABLE 123 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 196.
TABLE 124 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 197.
TABLE 125 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024–2031 (USD MILLION) 199.
TABLE 126 PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION) 200.
TABLE 127 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200.
TABLE 128 EUROPE: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 129 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 201.
TABLE 130 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 131 MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024–2031 (USD MILLION) 202.
TABLE 132 GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202.
TABLE 133 PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 203.
TABLE 134 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 135 EUROPE: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 204.
TABLE 136 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 137 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 205.
TABLE 138 MIDDLE EAST: PROBES MARKET, BY REGION, 2024–2031 (USD MILLION) 205.
TABLE 139 GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206.
TABLE 140 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 207.
TABLE 141 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 142 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 143 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 208.
TABLE 144 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 145 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 209.
TABLE 146 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 209.
TABLE 147 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 210.
TABLE 148 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 149 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 211.
TABLE 150 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 151 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212.
TABLE 152 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 213.
TABLE 153 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213.
TABLE 154 OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 214.
TABLE 155 NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214.
TABLE 156 EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 157 ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215.
TABLE 158 LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 159 MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 216.
TABLE 160 GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216.
TABLE 161 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024–2031 (USD MILLION) 218.
TABLE 162 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 219.
TABLE 163 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 219.
TABLE 164 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 165 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 220.
TABLE 166 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 167 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 221.
TABLE 168 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 221.
TABLE 169 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 222.
TABLE 170 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 171 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 223.
TABLE 172 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 173 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 224.
TABLE 174 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024–2031 (USD MILLION) 225.
TABLE 175 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 225.
TABLE 176 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 227.
TABLE 177 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 228.
TABLE 178 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 228.
TABLE 179 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 180 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 229.
TABLE 181 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 182 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 230.
TABLE 183 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 230.
TABLE 184 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 231.
TABLE 185 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 232.
TABLE 186 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 232.
TABLE 187 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 233.
TABLE 188 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 233.
TABLE 189 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 190 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 234.
TABLE 191 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 234.
TABLE 192 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 235.
TABLE 193 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 235.
TABLE 194 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 195 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 236.
TABLE 196 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 237.
TABLE 197 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 237.
TABLE 198 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 237.
TABLE 199 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 238.
TABLE 200 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 238.
TABLE 201 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 202 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 239.
TABLE 203 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 204 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 240.
TABLE 205 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 240.
TABLE 206 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 241.
TABLE 207 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 242.
TABLE 208 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 242.
TABLE 209 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 243.
TABLE 210 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 243.
TABLE 211 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 244.
TABLE 212 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024–2031 (USD MILLION) 244.
TABLE 213 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 245.
TABLE 214 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 245.
TABLE 215 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246.
TABLE 216 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246.
TABLE 217 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247.
TABLE 218 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 247.
TABLE 219 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247.
TABLE 220 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024–2031 (USD MILLION) 249.
TABLE 221 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 250.
TABLE 222 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 250.
TABLE 223 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 251.
TABLE 224 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 251.
TABLE 225 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 252.
TABLE 226 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 252.
TABLE 227 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 252.
TABLE 228 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 253.
TABLE 229 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 254.
TABLE 230 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 254.
TABLE 231 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 255.
TABLE 232 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 255.
TABLE 233 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024–2031 (USD MILLION) 256.
TABLE 234 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024–2031 (USD MILLION) 256.
TABLE 235 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 257.
TABLE 236 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 257.
TABLE 237 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 258.
TABLE 238 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 258.
TABLE 239 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 259.
TABLE 240 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 259.
TABLE 241 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 259.
TABLE 242 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 260.
TABLE 243 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261.
TABLE 244 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 261.
TABLE 245 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262.
TABLE 246 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 262.
TABLE 247 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 263.
TABLE 248 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 263.
TABLE 249 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265.
TABLE 250 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 266.
TABLE 251 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267.
TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 267.
TABLE 253 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268.
TABLE 254 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 268.
TABLE 255 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION) 269.
TABLE 256 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 269.
TABLE 257 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION) 269.
TABLE 258 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 270.
TABLE 259 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271.
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 271.
TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272.
TABLE 262 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 272.
TABLE 263 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 273.
TABLE 264 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 273.
TABLE 265 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 274.
TABLE 266 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION) 275.
TABLE 267 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 275.
TABLE 268 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276.
TABLE 269 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 276.
TABLE 270 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277.
TABLE 271 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024–2031 (USD MILLION) 277.
TABLE 272 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 277.
TABLE 273 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024–2031 (USD MILLION) 278.
TABLE 274 DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 279.
TABLE 275 NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 279.
TABLE 276 EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280.
TABLE 277 ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 280.
TABLE 278 LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281.
TABLE 279 MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 281.
TABLE 280 GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281.
TABLE 281 RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 282.
TABLE 282 NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283.
TABLE 283 EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 283.
TABLE 284 ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284.
TABLE 285 LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 284.
TABLE 286 MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 285.
TABLE 287 GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 285.
TABLE 288 MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 286.
TABLE 289 NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286.
TABLE 290 EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 287.
TABLE 291 ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 287.
TABLE 292 LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288.
TABLE 293 MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024–2031 (USD MILLION) 288.
TABLE 294 GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 288.
TABLE 295 ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 289.
TABLE 296 NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290.
TABLE 297 EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 290.
TABLE 298 ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY,